Copenhagen, Denmark — August 21, 2025 — Leads & Copy — Novonesis reported a 9% organic sales growth in the first half of the year and narrowed its full-year outlook range to 6-8%. According to President and CEO Ester Baiget, demand for the company’s biosolutions is strong, leading to an increase in the lower end of the full-year guidance. Despite currency headwinds, profitability remains solid. Cost synergies have reached a 100% run rate, and the adjusted EBITDA margin is at 37.4%. The company completed a EUR 100 million share buyback program and approved an interim dividend of 2.25 DKK (EUR 0.30) for the first half of 2025. Novonesis also announced its long-term financial targets towards 2030.
Strong organic sales growth of 9% (Q2: 8%), including ~1pp from price (Q2: ~1pp). Food & Health at 10% organic sales growth (Q2: 9%); Planetary Health at 9% organic sales growth (Q2: 7%). Emerging markets organic sales growth at 12% (Q2: 10%) and developed markets at 8% (Q2: 6%). Adjusted net profit increased by 23% (Q2: 19%). NIBD/EBITDA at 2.1x, including the closed acquisition of dsm-firmenich’s part of the Feed Enzyme Alliance on June 2, 2025. 2025 outlook: Organic sales growth range narrowed to 6-8% (previously 5-8%), and 7-9% excluding the exit from certain countries (previously 6-9%). Adjusted EBITDA margin is maintained at 37-38%, despite strong currency headwinds.
Investor Relations Contact: Tobias Bjorklund, +45 3077 8682, tobb@novonesis.com; Anders Enevoldsen, +45 5350 1453, adev@novonesis.com; Katrine Spedtsberg Poulsen, kats@novonesis.com. Media Relations Contact: Jens Gamborg, +45 3077 7182, jgam@novonesis.com
Source: Novonesis
